Human IgM antibodies to chemokine receptors
OwnerPeter I. Loboinventor
Life of this patent
Estimating the term…
Abstract
Human sera from normal (i.e., non-HIV infected) individuals contain certain IgM autoantibodies reactive to chemokine and other lymphocyte-surface receptors. A subset of these IgM autoantibodies that bind to such receptors, particularly CXCR4 and CCR5 receptors, can inhibit HIV-1 from infecting cells. Progression from an asymptomatic HIV-1 infected state to AIDS is determined in part by the level of IgM autoantibodies that inhibit HIV-1 from infecting cells. The claimed invention described herein is a method of using these isolated antibodies for the inhibition of the progression of virus-mediated diseases.
Claims9
A method of inhibiting HIV cell entry comprising administering an effective amount of isolated heterogeneous anti-leukocyte receptor IgM antibody that targets at least one of the chemokine receptors selected from the group consisting of CCR5, CCR3, CXCR4, and CCR2B, and wherein said IgM antibody is effective to inhibit HIV cell entry.
Dependencies are inferred from the claim text.